Mission

The Mission of the Johns Hopkins Center for Tuberculosis Research (CTR) is to contribute to global tuberculosis control through a range of research and training initiatives in epidemiology, diagnostics, drug development, clinical trials, pathogenesis and basic biology. The CTR, founded in 1998, is comprised of a multi-disciplinary team of scientists working to combat Mycobacterium tuberculosis, a pathogen that causes 1.5 to 2 million deaths every year. Our faculty is drawn from the Schools of Medicine, Bloomberg School of Public Health and Nursing, with a research portfolio that is broad and interdisciplinary. Our major strengths are molecular biology, epidemiology, clinical trials, drug development and mathematical modeling; additional areas of emphasis include animal models, pathogenesis, vaccine development, behavioral research, immunology, and diagnostics.

While research is a primary focus, developing the next cadre of scientists who will contribute to future control efforts is also a major goal. Students from medicine, public health, and nursing have found that the range of topics and locations offer excellent training opportunities. With the slogan, “From bench to bedside and beyond,” the CTR covers everything from genetic epidemiology of TB to population-level studies that have played a major role in forming global policies for TB control.

Events

«

March 2017

»
S
M
T
W
T
F
S
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·

Projects

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More

Scale-up and implementation of TB diagnostics...

We are evaluating the implementation, cost-effectiveness, and potential epidemiological impact of scaling up Xpert across 19...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

Population-level impact of isoniazid...

We are collaborating with a team that conducted a randomized trial of IPT in Khayelitsha, South Africa, to extend their findings...

Read More

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More